ライフサイエンスコーパス: Flt3 ligand

1 n DC development in vitro in the presence of Flt3 ligand.

2 okine combination of steel factor, IL-7, and Flt3 ligand.

3 rentiation into IPCs/pre-DC2 in culture with FLT3 ligand.

4 -1 myeloid leukemia cells indicates that the FLT3 ligand.

5 in cultures of BM precursors stimulated with Flt3 ligand.

6 a cell lines (n = 5) bound little to no 125I-FLT3 ligand.

7 0 even after the induction of high levels of Flt3 ligand.

8 th sites shared an intrinsic requirement for Flt3 ligand.

9 odies (mAb) capable of preventing binding of FLT3 ligand.

10 nerated from mouse bone marrow cultures with FLT3-ligand.

11 on BM stromal cells supplemented with IL-7 + FLT3-ligand.

12 cells supplemented with interleukin (IL)-7 + FLT3-ligand.

13 or (M-CSFR) and Fms-like thyrosine kinase 3 (Flt3) ligands.

14 is could be accelerated therapeutically with flt3 ligand, a growth factor that stimulates the differe

15 Treatment with Flt3 ligand, a hematopoietic growth factor that dramatic

16 t treatment of advanced cancer patients with Flt3 ligand, a hematopoietic growth factor, expanded DCs

17 Abs against lymphotoxin A, TNF-alpha, and/or flt3 ligand abolished the ability of CS1 on the B cell p

18 iven nasal OVA plus an adenovirus expressing Flt3 ligand (Ad-FL) showed early expansion of CCR5(+)/CC

19 We have recently shown that Flt3 ligand administration dramatically increases dendri

20 ins to the minimization of recombinant human Flt3 ligand aggregation and its potential role for deter

21 l in pDCs generated in vitro by culture with Flt3 ligand and ex vivo in sorted splenic pDCs.

22 number of TIDCs, the therapeutic benefit of Flt3 ligand and GM-CSF treatment is minimal.

23 of the IL-7R, and require costimulation with Flt3 ligand and IL-7 to generate B cells in vitro.

24 sarcomas with the combination of recombinant Flt3 ligand and recombinant granulocyte-macrophage colon

25 t numbers of DCs to peripheral tissues using Flt3 ligand and then delivering a tumor-associated Ag an

26 ) myeloid DCs is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulatin

27 cyte macrophage colony-stimulating factor or FLT3 ligand) and costimulation by agonistic alpha-4-1BB

28 au, amyloid beta peptide 1-42 (Abeta(1-42)), Flt3 ligand, and fractalkine levels in CSF in a large co

29 rs such as stem cell factor, thrombopoietin, Flt3 ligand, and interleukins have shown promising resul

30 egative murine marrow cells cultured in TPO, Flt3 ligand, and SCF, without affecting the rate of cell

31 The combination of thrombopoietin, Flt3 ligand, and stem cell factor upregulated survivin e

32 colony-stimulating factor, stem cell factor, flt3 ligand, and thrombopoietin, to this SCEPF activity.

33 ukin 3 (IL-3), IL-6, stem cell factor (SCF), Flt3 ligand, and thrombopoietin.

34 ls to the early-acting cytokines kit ligand, flt3 ligand, and thrombopoietin.

35 -stimulating factor, stem cell factor, flk-2/flt3 ligand, and thrombopoietin.

36 response to a cocktail of stem cell factor, flt3 ligand, and thrombopoietin.

37 -M-DC CM was the only one that enhanced SCF, Flt3 ligand, and TPO expansion of myeloid progenitor cel

38 ow arises as to whether these high levels of FLT3 ligand are actually promoting relapse, and, if so,

39 Unexpectedly, a robust Flt3 ligand-associated proliferative recovery response s

40 or megakaryocyte nuclear maturation, nor did FLT3 ligand augment the effects of thrombopoietin on the

41 Scatchard analysis of 125I-FLT3 ligand binding data shows that three myeloid leukem

42 gand production was established; whereas the Flt3 ligand blunted the inhibitory effects of AC220, the

43 responsive to superphysiological amounts of Flt3 ligand but was not dependent on Flt3 for its homeos

44 Flt3 ligand, but not thymic stromal-derived lymhopoietin

45 Human Flt3 ligand can expand dendritic cells (DC) and enhance

46 te-macrophage colony-stimulating factor, and Flt3 ligand, CD45+/lineage-/c-kit+/FcepsilonRI+ cells be

47 Following treatment of mice with Flt3 ligand, coadministration of immunostimulatory DNA a

48 ysozyme(+)) colonies when grown in IL-7- and Flt3 ligand-containing media.

49 on between DCs and cell-free HTLV-1, we used FLT3 ligand-cultured mouse bone marrow-derived DCs (FL-D

50 B cells from Flt3 ligand-deficient mice have impaired IL-4R signaling

51 Absence of Flt3 signaling in Flt3 ligand-deficient mice results in impaired IgG1 CSR

52 Flt3 ligand-dependent generation of CD8alpha(+) cDCs in

53 ir virtual lack of IL-12 production, whereas Flt3 ligand-derived dendritic cells produced IL-12 and a

54 oreover, NOD bone marrow cells cultured with Flt3-ligand developed a heat-stable antigen-positive/Ly6

55 FLT3 ligand did not promote colony forming unit megakary

56 By contrast, in Flt3 ligand-driven DC differentiation, activation of AF-

57 l (E2) has been shown to regulate GM-CSF- or Flt3 ligand-driven dendritic cell (DC) development throu

58 (CD135), and stimulation of the receptor via FLT3 ligand either in vivo or in vitro is known to drive

59 was expanded in media containing recombinant flt3 ligand, erythropoietin, and PIXY321, using stromal-

60 highly conserved, 18 aa sequence within the flt3 ligand extracellular domain is required for flt3 re

61 or numerous growth factors (kit ligand [KL], FLT3 ligand, fibroblast growth factor-2 [FGF-2], vascula

62 increases in donor liver DC as the result of Flt3 ligand (FL) administration and the resulting augmen

63 Systemic Flt3 ligand (FL) administration in mice induced a signif

64 igh cells were maintained in the presence of Flt3 ligand (FL) alone, and increased in response to FL

65 hereby extrinsic microenvironmental proteins FLT3 ligand (FL) and fibroblast growth factor 2 (FGF2) p

66 was recognized that other factors including flt3 ligand (FL) and G-CSF expand various DC subsets in

67 Here we investigated the effect of flt3 ligand (FL) and granulocyte colony-stimulating fact

68 e CD11c(+)B220(+) pDCs can be generated with Flt3 ligand (FL) as the sole exogenous differentiation/g

69 e tyrosine kinase activity in the absence of FLT3 ligand (FL) binding, and when expressed in cytokine

70 istration of a naked cDNA plasmid expressing Flt3 ligand (FL) cDNA (pFL) enhanced CD4(+) Th2-type, cy

71 Treatment of mice with human Flt3 ligand (FL) dramatically increases the number of DC

72 Flt3 ligand (FL) dramatically increases the number of im

73 The cytokine FLT3 ligand (FL) enhances dendritic cell (DC) generation

74 Flt3 ligand (FL) enhances hematopoietic cell proliferati

75 In this study, we assessed a cDNA vector for Flt3 ligand (FL) for its potential to enhance mucosal im

76 We recently showed that the flt3 ligand (FL) has a unique ability to interact with i

77 Flt3 ligand (FL) has been proposed as a possible modulat

78 studies using stroma-free short term assays, Flt3 ligand (FL) has been shown to induce proliferation

79 Mice deficient for Hoxa9, Flt3, or Flt3 ligand (FL) have reduced numbers of lymphoid-primed

80 We have investigated the role of flk2/flt3 ligand (FL) in B cell lymphopoiesis.

81 , we report a synergistic role for IFN-I and Flt3 ligand (FL) in pDC development from common lymphoid

82 To expand on the functional properties of Flt3 ligand (FL) in vivo we treated nonhuman primates wi

83 Daily injection of mice of Flt3 ligand (FL) into mice transiently expands both subs

84 Flt3 ligand (FL) is a hematopoietic growth factor that i

85 Flt3 ligand (FL) is a member of a small family of growth

86 Flt3 ligand (FL) is a potent hemopoietic growth factor t

87 sed patients, we investigated whether plasma FLT3 ligand (FL) levels could influence the efficacy of

88 We hypothesized that the cytokine FLT3 ligand (FL) might be able to replace the maintenanc

89 lation of wild-type (WT) FLT3 by coexpressed FLT3 ligand (FL) occurs in many other cases.

90 ietic stem-progenitor cell mobilizing factor flt3 ligand (FL) on donor leukocyte microchimerism in no

91 The effects of a novel cytokine FLK2/FLT3 ligand (FL) on human fetal bone marrow-derived CD34

92 The effect of chronic expression of flt3 ligand (FL) on in vivo hematopoiesis was studied.

93 igated the effects of in vivo treatment with flt3 ligand (FL) on murine hematopoiesis, including mobi

94 ery followed by intramyocardial injection of FLT3 ligand (FL) or vehicle into the infarct border zone

95 Systemic treatment with Flt3 ligand (FL) results in a marked increase of DCs in

96 Administration of FLT3 ligand (FL) results in a reversible accumulation of

97 burn-injured mice with the DC growth factor FLT3 ligand (FL) significantly increases resistance to b

98 The recently cloned flt3 ligand (FL) stimulates the growth of primitive hema

99 ion of FLT3-transfected cells was delayed by FLT3 ligand (FL) stimulation.

100 ats 1-4, 5b, or 6, was potently activated by Flt3 ligand (FL) stimulation.

101 IMC-EB10 blocks the binding of FLT3 ligand (FL) to soluble FLT3 in ELISA and competes w

102 Notably, Flt3 ligand (FL) treatment of NOD donors expanded FC tot

103 timulation, and both expand and mature after Flt3 ligand (FL) treatment.

104 Here we show that administration of Flt3 ligand (FL), a cytokine capable of inducing large n

105 cible system to conditionally express murine Flt3 ligand (FL), a potent hemopoietic growth factor tha

106 al different growth factors, including human flt3 ligand (FL), alone and in combination with granuloc

107 factors, interleukin-2 (IL-2), IL-12, IL-15, Flt3 ligand (FL), and granulocyte-macrophage colony-stim

108 ulation of survivin by thrombopoietin (Tpo), Flt3 ligand (FL), and stem cell factor (SCF) occurred in

109 pare and contrast the expression patterns of Flt3 ligand (FL), c-Kit ligand (KL), and macrophage colo

110 imiting dilutions with interleukin-7 (IL-7), flt3 ligand (FL), c-kit ligand (KL), IL-3, IL-2, and AFT

111 owth, but synergized with c-kit ligand (KL), flt3 ligand (FL), or IL-3 to potently enhance clonogenic

112 he recently cloned hemopoietic growth factor flt3 ligand (FL), which is highly effective in mobilizin

113 k itself was tyrosine phosphorylated by both FLT3 ligand (FL)-activated FLT3-WT and constitutively ac

114 Flt3 ligand (FL)-derived DC function was tested as a sti

115 se domain (TKD) appear to activate FLT3 in a FLT3 ligand (FL)-independent manner.

116 bopoietin (TPO), c-kit ligand (KL), and flk2/flt3 ligand (FL).

117 he recently cloned hemopoietic growth factor Flt3 ligand (FL; 10 microg/day for 10 days) resulted in

118 Fms-like tyrosine kinase-3 (Flt3) ligand (FL) and Interleukin-7 (IL-7) are cytokines

119 Fms-related tyrosine kinase 3 (Flt3)-ligand (FL) promotes the proliferation, differenti

120 re injected with Fms-like tyrosine kinase 3 (Flt3)-ligand (FL) to expand dendritic cells (DCs) and we

121 Injection of mice with the cytokine Flt3-ligand (FL) dramatically expands mature lymphoid an

122 leukin-3 (IL-3), stem cell factor (SCF), and flt3-ligand (FL) for a 36-hour incubation period during

123 phage colony-stimulating factor (GM-CSF) and flt3-ligand (FL) induce the development of dendritic cel

124 FLT3-ligand (FL) is a recently described cytokine that s

125 inant chimera of the extracellular domain of Flt3-ligand (FL) linked to a model antigen may potential

126 aper we report that administration of either Flt3-ligand (FL) or G-CSF to healthy human volunteers dr

127 Treatment with stem cell factor (SCF), Flt3-ligand (FL), IL-3, and GM-CSF and measurement by mu

128 consisting of either stem cell factor (SCF), Flt3-ligand (FL), interleukin-3 (IL-3), or IL-6 for 7 da

129 In the present study, the flt3-ligand (FL), which, in combination with other cytok

130 Here we describe a flt3-ligand (FL)-dependent BM culture system that genera

131 s in IL-6, IL-7, stem cell factor (SCF), and flt3 ligand (flt3-L) for 5-6 d followed by IL-15 alone f

132 Flt3 ligand (Flt3-L) is a growth factor for dendritic ce

133 Flt3 ligand (Flt3-L) is critical for instructing DC gene

134 intracellular bacteria, we treated mice with Flt3 ligand (Flt3-L) to increase DCs in vivo and challen

135 ned the in vivo effects of recombinant human Flt3 ligand (Flt3-L), a recently cloned potent hemopoiet

136 lished a humanized mouse model incorporating FLT3-ligand (FLT3-L) administration after hematopoietic

137 ed the utility of a novel protocol involving Flt3-ligand (Flt3-L) and granulocyte colony-stimulating

138 Flt3-Ligand (Flt3-L) is a stimulatory cytokine for a var

139 Flt3-ligand (Flt3-L) is an early acting costimulatory cy

140 FLT3-ligand (FLT3-L) represents a key IPC differentiatio

141 We assessed the in vivo efficacy of Flt3-ligand (Flt3-L) treatment in C57BL/6 mice bearing a

142 The cytokine Flt3 ligand (Flt3L) also has been shown to generate BM D

143 CL12 expression after HSPC mobilization with Flt3 ligand (Flt3L) and stem cell factor (SCF).

144 response were enhanced by prior injection of Flt3 ligand (Flt3L) at a dose and schedule that signific

145 The cytokine Flt3 ligand (Flt3L) controls the development of DCs and

146 overexpression of the hematopoietic cytokine Flt3 ligand (Flt3L) expands NKDC in various organs from

147 Here we show that, like GM-CSF, the cytokine Flt3 ligand (Flt3L) expressed in B16 and coupled with CT

148 Flt3 ligand (flt3L) has potent effects on hemopoietic pr

149 the present study, daily injection of human Flt3 ligand (Flt3L) into mice results in a dramatic nume

150 The flt3 ligand (flt3L) is a growth factor for hematopoietic

151 The cytokine Flt3 ligand (Flt3L) is critical for the generation and m

152 Flt3 ligand (Flt3L) is transiently induced in the serum

153 Mobilization of mice with Flt3 ligand (Flt3L) or Flt3L and granulocyte-macrophage

154 The Flt3-Flt3 ligand (Flt3L) pathway is critically involved in th

155 Flt3 ligand (Flt3L) potently induced equal expansion of

156 Flt3 ligand (Flt3L) promotes survival of lymphoid progen

157 ll homeostasis and adaptive immunity through Flt3 ligand (Flt3l) release.

158 FLT3 ligand (FLT3L) stimulates primitive hematopoietic c

159 Indeed, flt3 ligand (flt3L) treatment of athymic mice subjected

160 c into immunogenic APC by treating mice with Flt3 ligand (Flt3L), a DC growth factor, and then immuni

161 immunity and tolerance, we treated mice with Flt3 ligand (Flt3L), a growth factor that expands DC in

162 and used as vaccines or generated in vivo by Flt3 ligand (Flt3L), a potent stimulator of DC and natur

163 culture in IL-7, stem cell factor (SCF), and flt3 ligand (flt3L), followed by IL-15 alone.

164 ion (ITD) in FLT3, the receptor for cytokine FLT3 ligand (FLT3L).

165 etreatments with fms-like tyrosine kinase-3 (Flt3) ligand (Flt3L), a dendritic cell growth factor, in

166 We hypothesized that Flt3-ligand (Flt3L) therapy, which expands DCs in vivo,

167 model, we developed protocols for measuring Flt3 ligand (Flt3lg) and serum amyloid A1 (Saa1) in smal

168 ere cultured with IL-7, stem cell factor and flt3 ligand, followed by IL-15, they were able to differ

169 of macrophage colony-stimulating factor and flt3 Ligand for 6 days to generate monocytic cells at al

170 ocompatibility complex class II, and require FLT3 ligand for development (T(DC)).

171 rom myeloid progenitors and are dependent on Flt3-ligand for their development.

172 oma cells expressing either GM-CSF (Gvax) or Flt3-ligand (Fvax) combined with antibody blockade of th

173 These data suggest that Flt3 ligand + GM-CSF therapy of murine tumors fails at a

174 filtration of tumors by CD4(+)CD25(+) TIL in Flt3 ligand + GM-CSF-treated mice, this could reflect th

175 ed medium supplemented with kit ligand, flk2/flt3 ligand, GM-CSF, c-mpl ligand, erythropoietin, and I

176 ily treatment of mice with recombinant human Flt3 ligand (huFlt3L) results in a dramatic numerical in

177 onocytes and DC by conditional expression of Flt3 ligand in animals expressing CCL2 in the CNS promot

178 BM stromal cells are comparable with IL-7 + FLT3-ligand in supporting proliferation of BLIN-4L cells

179 spension culture without FL We conclude that FLT3 ligand, in conjunction with IL-3, IL-6, and SCF, pr

180 In contrast, administration of Flt3 ligand increases the CD11c(hi) DC population, which

181 LIN-4L expansion on BM stromal cells is IL-7/FLT3-ligand independent.

182 IL-6, stem cell factor, thrombopoietin, and Flt3 ligand induced Ccn3/Nov mRNA over 100-fold in WT (c

183 orted exponential growth of L. monocytogenes Flt3 ligand-induced cultures yielded CD103(+)CD11c(+) ce

184 hat TGF-beta2 at low concentrations enhances flt3 ligand-induced growth of HSPCs, while it is potentl

185 inhibition of IFN-alphabeta was observed in FLT3 ligand-induced murine DCs, purified murine myeloid

186 cellularity and also is required to mediate Flt3 ligand-induced NK cell expansion in vivo.

187 and defective in Fms-like tyrosine kinase-3(Flt3) ligand-induced, but not in granulocyte macrophage-

188 ralysis in 100% of the mice within 9 days of Flt3 ligand induction.

189 r the control of fms-like tyrosine kinase 3 (Flt3) ligand, inhibitor of DNA protein 2 (Id2), and IFN

190 spension in the presence of KIT ligand, FLK2/FLT3 ligand, interleukin-6 (IL-6), and erythropoietin wi

191 The rates of FLT3 ligand internalization and degradation were determi

192 FLT3 ligand is a hematopoietic growth factor that plays

193 strated by its failure to inhibit the bovine flt3 ligand isoform 1 binding to the human flt3 receptor

194 ng structure was confirmed by testing bovine flt3 ligand isoform 1 constructs truncated at specific r

195 evel, the extracellular domain of the bovine flt3 ligand isoform 1 is 81 and 72% identical with the e

196 Bovine flt3 ligand isoform 1, but not 2, bound the human flt3 r

197 Two conserved bovine flt3 ligand isoforms, which differ in a defined region w

198 FLT3 ligand levels did not rise to levels seen in prior

199 CS1 activation enhanced mRNA transcripts of flt3 ligand, lymphotoxin A, TNF, and IL-14.

200 landin E(2) (PGE(2)) is required for optimal Flt3 ligand-mediated DC development and regulates expres

201 Because the Flt3 ligand-mediated differentiation pathway is importan

202 little is known about the effects of murine Flt3 ligand (mFlt3L) on mouse DC development and functio

203 -15(-/-) as well as IL-15Ralpha(-/-) but not flt3 ligand(-/-) mice expressed much lower levels of Ly-

204 olonies in the presence of interleukin 7 and flt3 ligand migrate to thymus-expressed chemokine (TECK)

205 In addition, we evaluated the effect of FLT3 ligand on megakaryocytic colony growth and nuclear

206 tiated from the BM of UV-chimeric mice using FLT3 ligand or GM-CSF + IL-4, the cells maintained a red

207 on by granulocyte-colony stimulating factor, flt3 ligand, or both.

208 Particularly, with CSF Flt3 ligand, PD could be clearly differentiated from mul

209 d that a combination of a plasmid-expressing Flt3 ligand (pFL) and CpG oligodeoxynucleotides (CpG ODN

210 mmunized with PspA plus a plasmid expressing Flt3 ligand (pFL) cDNA as a mucosal adjuvant showed sign

211 nce between the opposing forces of AC220 and Flt3 ligand production was established; whereas the Flt3

212 Notably, administration of flt3 ligand rapidly reverses immunoparalysis in vivo, ac

213 FLT3/ITD by lestaurtinib caused by exogenous FLT3 ligand, resistance to sorafenib caused by the D835Y

214 xtracellular domains of the human and murine flt3 ligands, respectively, whereas isoform-2 has a dele

215 Stimulation of patient samples with FLT3 ligand resulted in autophosphorylation of the FLT3

216 concentrations of thrombopoietin/Kit-ligand/Flt3-ligand resulted in a 400-fold expansion of total he

217 Strikingly, treatment of NOD mice with Flt3-ligand significantly decreased insulitis and progre

218 ne AFT024 fetal liver stromal cells and with Flt3-Ligand, stem cell factor, and interleukin-7.

219 Overall, the flt3 ligand structure required for function is markedly

220 This definition of the required flt3 ligand structure will facilitate development of ago

221 identify the fetal liver tyrosine kinase 3 (flt3) ligand structure required for binding and function

222 Conversely, in Flt3 ligand-supplemented cultures initiated from the sam

223 t of this, CD1d was required for the SCF and Flt3 ligand synergistic enhancement of CSF induction of

224 They remain highly responsive to FLT3 ligand, the levels of which rise several-fold durin

225 ts on differentiation mediated by GM-CSF and Flt3 ligand, the two cytokines that regulate DC differen

226 38(-) cells derived from FLV were exposed to flt3-ligand, thrombopoietin, stem cell factor (SCF), or

227 nation of Abs against GM-CSF, IL-3, and anti-Flt3 ligand to achieve maximum neutralization.

228 k thermal reversibility to the propensity of Flt3 ligand to aggregate once unfolded in the Tm plateau

229 use bone marrow cells can be used along with Flt3 ligand to conditionally immortalize early hematopoi

230 Crosslinking of 125I-FLT3 ligand to FLT3 receptors on the surface of ML-1 mye

231 New efforts focus on blocking the binding of FLT3 ligand to its receptor as a means of inhibiting aut

232 degradation were determined by binding 125I-FLT3 ligand to ML-1 cells and acid stripping to distingu

233 the FLT3 receptor may target the effects of FLT3 ligand to primitive hematopoietic cells and to myel

234 he regulatory proteins VEGF, HGF, FGF-2, KL, FLT3 ligand, TPO, IL-16, IGF-1, transforming growth fact

235 C3H (H2(k)) recipients of liver grafts from Flt3 ligand-treated B10 donors were given neutralizing a

236 hat the mature DC subsets (C, D, and E) from Flt3 ligand-treated mice differ with respect to phenotyp

237 antially from subsets recruited in normal or Flt3 ligand-treated mice or using GM-CSF protein injecti

238 ed with minimal amounts in DC from normal or Flt3 ligand-treated mice.

239 Finally, postsepsis Flt3 ligand treatment increased the number of DCs and im

240 Therefore, Flt3-ligand treatment and/or the establishment of mixed

241 Internalized 125I-FLT3 ligand was detected within 5 minutes after binding

242 led to protect against tumors in which human Flt3 ligand was protective, but depletion of CD4(+) T ce

243 Flt3 ligand was required during the 7-day ex vivo cultur

244 Using human 125I-FLT3 ligand, we have identified and characterized surfac

245 The levels of blood Flt3 ligand were also measured to evaluate the radioimmu

246 um levels of the hematopoietic growth factor Flt3 ligand were dramatically elevated.

247 nes, ie, G-CSF plus kit ligand or G-CSF plus Flt3-ligand were used with anti-VLA4 in primates and mic

248 s systemic delivery of the DC growth factor, Flt3 ligand, which dramatically increased the number of

249 By contrast, livers from donors treated with Flt3 ligand, which dramatically increases hepatic inters

250 Candidate cytokines included IFN-gamma and Flt3 ligand, which were also produced in response to IL-

251 we combined a dendritic cell growth factor, Flt3 ligand, with a dendritic cell activator, immunostim